evidencegaps
Primary study · included by 1 review

Dysfunction of the Salivary and Lacrimal Glands After Radioiodine Therapy for Thyroid Cancer: Results of the START Study After 6-Months of Follow-Up.

Baudin 2023 · Baudin Clémence, Bressand Alice, Buffet Camille, et al. · Thyroid : official journal of the American Thyroid Association · 2023

Included by

Salivary and lacrimal disorders in patients treated with radioiodine for differentiated thyroid cancer.
Non-Cochrane · prognostic · 2026 · cited as Baudin 2023 · Supplementary Table S3 (included studies); Figs. 1-3
Outcome this study informsPooled effectEvidenceCertainty
Xerostomia (pooled prevalence)
Radioiodine (I131) therapy · between 2 and 6 months after RIT
Prevalence 0.37 [0.28, 0.47]4 studies · 392 participantsGRADE not reported

1 including review in total.